Compare Amphastar Pharmaceuticals Inc (AMPH) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Stanley Black & Decker, Inc. trades at $103.91 (market cap $15.50B). The key difference: Stanley Black & Decker, Inc. is far larger — about 17.9× Amphastar Pharmaceuticals Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.27% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SWK | |
|---|---|---|
Market Cap | $863.95M | $15.50B |
Sector | Health | — |
52-Week High | $30.81 | $104.00 |
52-Week Low | $16.87 | $62.12 |
Enterprise Value | $1.26B | $19.67B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Stanley Black & Decker (SWK) trades at $103.89, up 2.82% today, showing strong momentum after recent earnings beats. The stock demonstrates improving fundamentals with Q2 2026 EPS of $1.57 beating estimates by 30%, while technical indicators show bullish moving averages but overbought RSI levels. Recent corporate developments include debt reduction of $1.7 billion and a dividend increase to $0.84 per share.
SWK presents a mixed outlook with strong operational improvements and margin expansion offset by valuation concerns. The stock trades above analyst consensus target of $93.67, suggesting limited near-term upside. Key opportunities include continued margin recovery and market share gains, while risks involve economic sensitivity and competitive pressures in the tools industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
